{
  "payload": {
    "molecule": "Metformin",
    "recommendation": "Monitor",
    "market_score": 61,
    "innovation_story": "Metformin shows emerging anti-fibrotic and anti-inflammatory activity in NASH and SSc cohorts, but controlled data remains limited outside metabolic endpoints.",
    "workers": {
      "clinical": {
        "summary": "Small investigator-sponsored trials report mild liver fat reduction in NASH with metformin add-on; metabolic endpoints outperform fibrosis surrogates.",
        "confidence": 0.55,
        "confidence_band": "medium",
        "evidence": [
          {
            "type": "Trial",
            "text": "Metformin + lifestyle yielded a 12% relative reduction in liver fat over 36 weeks (NCT04511234).",
            "url": "https://clinicaltrials.gov/study/NCT04511234",
            "confidence": 0.52
          }
        ]
      },
      "literature": {
        "summary": "PMC studies highlight AMPK-driven inhibition of stellate cell activation plus glycemic control benefits relevant to fibrotic settings.",
        "confidence": 0.58,
        "confidence_band": "medium",
        "evidence": [
          {
            "type": "Mechanism",
            "text": "Metformin activated AMPK and reduced alpha-SMA expression in hepatic stellate cells in vitro.",
            "url": "https://pubmed.ncbi.nlm.nih.gov/33551234/",
            "confidence": 0.57
          }
        ]
      },
      "patent": {
        "summary": "Crowded generics space; combo IP around metabolic-fibrotic overlap is narrow but enforceable.",
        "confidence": 0.48,
        "confidence_band": "low",
        "evidence": [
          {
            "type": "Patent",
            "text": "WO2023099981 covers metformin + GLP-1 combos targeting metabolic fibrosis but lacks organ-specific claims.",
            "url": "https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023099981",
            "confidence": 0.44
          }
        ]
      },
      "market": {
        "summary": "$0.9B upside if metabolic fibrosis segmentation succeeds; payer pushback expected without biopsy-backed endpoints.",
        "confidence": 0.5,
        "confidence_band": "low",
        "evidence": [
          {
            "type": "Market",
            "text": "Consultant panel estimated $0.9B TAM assuming 15% adoption in NASH clinics by 2029.",
            "url": "https://example.org/market/metformin",
            "confidence": 0.48
          }
        ]
      }
    },
    "quality": {
      "status": "investigate",
      "alerts": {
        "clinical": ["Low evidence coverage (1/2)", "Evidence monoculture (single unique source)"],
        "patent": ["Low precision proxy (0.44 < 0.50)"],
        "market": ["Low precision proxy (0.48 < 0.50)"]
      }
    }
  }
}
